Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02538653
Other study ID # KBE042
Secondary ID
Status Completed
Phase N/A
First received August 31, 2015
Last updated September 13, 2017
Start date September 2015
Est. completion date December 2015

Study information

Verified date September 2017
Source Mondelez International, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed at determining the 4-hours postprandial blood glucose and insulin responses to the ingestion of cereal product differing by their SDS content.


Description:

This study aimed at determining the 4-hours postprandial blood glucose and insulin responses to the ingestion of cereal product differing by their SDS content. It is a laboratory-based research study with an open cross-over design, including 20 healthy non-smoking voluntary subjects, aged from 18 to 45 years. 2 test sessions per subject are included in the study. Foods are consumed in a random order according to a randomisation list.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Aged between 18-45 years.

- Non-smoker.

- BMI values between 19-30 kg/m2 (bounds included). Around half of the subjects will be normal weight and the other half overweight.

- Ethnicity. Subjects should have the closest characteristics compared to the American population. Not less than 75% but not more than 90% of the subjects should be Caucasian. Not more than 10% of the subjects will be of Asian or Asian Indian descent. The remaining subjects will be from other ethnic groups except from Australian Aborigines.

- Healthy subjects with:

- Normal glucose tolerance (fasting blood glucose < 6.0 mmol/L during the first test session and results of oral glucose tolerance test conducted within the last 30 days within recommendations (fasting blood glucose < 6.0 mmol/L, 120 minute glucose < 8.9 mmol/L))

- Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol);

- Normal systolic blood pressure (100-150 mmHg);

- Normal diastolic blood pressure (60-90 mmHg);

- Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).

- Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.

- Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week)

- Able to fast for at least 10 hours the night before each test session

- Able to refrain from eating legumes and drinking alcohol the day before each test session.

- Subject covered by social security or covered by a similar system

- Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely tointerfere with metabolism or dietary habits

- Subject having given written consent to take part in the study.

Exclusion Criteria:

- Following a restrictive diet.

- Family history of Diabetes Mellitus or obesity

- Suffering from any clinical, physical or mental illness.

- Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).

- Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication)

- Subject from the Australian Aboriginal ethnicity.

- Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.

- Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.

- Subject having taken part in another clinical trial within the last week.

- Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial.

- Subject undergoing general anaesthesia in the month prior to inclusion.

- Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Sandwich biscuit high in SDS
Consumption of the high SDS product (50g) alone with a glass of water
Co-extruded cereal low in SDS
Consumption of the low SDS product (48.3 g) alone with a glass of water

Locations

Country Name City State
Australia University of Sydney Sydney New South Wales

Sponsors (2)

Lead Sponsor Collaborator
Mondelez International, Inc. University of Sydney

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Other The plasma glucose peak value and the time for this latter will also be calculated. 4 hours after food consumption
Other The plasma insulin peak value and the time for this latter will also be calculated. 4 hours after food consumption
Primary Postprandial changes in plasma glucose levels over 2 hours (iAUC [0-120 min]) after consumption of the test products 2 hours after food consumption
Secondary Postprandial changes in glycaemia over 3 hours (iAUC [0-180]), 4h (iAUC[0-240]), during the second part of the morning (iAUC [120-240] and iAUC[180-240]) following the intake of the test products will be analysed. 4 hours after food consumption
Secondary Postprandial changes in insulinemia over 2 hours (iAUC [0-120]), over 3 hours (iAUC [0-180]), 4 hours (iAUC[0-240]), during the second part of the morning (iAUC [120-240] and iAUC [180-240]) following the intake of the test products will be analysed. 4 hours after food consumption